Seeking to encourage drug companies to conduct more clinical trials of innovative medicines in China, the Chinese government has proposed new protections on pharmaceutical data. Under the draft proposal, the China Drug Administration (CDA) would expand data exclusivity—the protection of clinical data... Read More
General healthcare spending in South Korea jumped by 6.8% on average each year between 2005 and 2015, according to a report released in May by the Korea Institute for Health and Social Affairs. The spending, fueled by an aging society, a fast... Read More
In May, the Chinese government published its first national list of rare diseases, a welcome development for foreign pharmaceutical companies eager to market treatments for their products there. The list of 121 diseases identified as rare was published by five Chinese government... Read More
Beginning November 1, 2018, high-risk medicines sold in India will be required to carry warnings on the packaging, part of a series of moves by the country’s Ministry of Health and Family Welfare to toughen labelling norms on pharmaceuticals. Under the new... Read More
In a step forward for the advancement of health research in South Korea, patients participating in clinical trials aimed at advancing public health are now covered by the country’s vaunted national health insurance system. The change went into effect on May 1.... Read More
Chronic obstructive pulmonary disease (COPD) is more prevalent in China than anywhere else in the world, afflicting more than 8.6% of adults, according to a new study by researchers at Tulane University. Almost 100 million people in China suffer from the group... Read More
A new law implemented by Korea in January requires pharmaceutical and medical device companies to track in minute detail money spent and benefits provided to a broad spectrum of medical professionals. Called the Sunshine Act, the law is part of an aggressive... Read More
Seeking to counter the country’s growing reliance on foreign drug imports, China’s government is planning massive investment in its own pharmaceutical industry over the next seven years. Chinese pharmaceutical giants most likely to benefit from the plan include Jiangsu Hengrui Medicine, CSPC... Read More
A claim by the leading U.S. pharmaceutical industry lobby that South Korea unfairly favors its own drug manufacturers over foreign firms is receiving strong pushback by the Korean government. Earlier this year, Pharmaceutical Research and Manufacturers of America (PhRMA) argued to the... Read More
In its latest effort to rein in spiraling healthcare costs for its aging population, Japan plans to help Japanese producers of generic drugs construct factories in Asian countries where labor costs are lower than in Japan. The move is part of a... Read More